{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:48:46Z","timestamp":1785437326328,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaip.2019.05.047","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T23:35:24Z","timestamp":1560382524000},"page":"2739-2749.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions"],"prefix":"10.1016","volume":"7","author":[{"given":"Hye Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Il","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hee","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Yeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Ryun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Woo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.05.047_bib1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaip.2019.05.047_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"Gout. N Engl J Med"},{"key":"10.1016\/j.jaip.2019.05.047_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2019.05.047_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.047_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaip.2019.05.047_bib6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions","volume":"44","author":"Ke","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib7","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2019.05.047_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2019.05.047_bib9","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2019.05.047_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/RHU.0b013e31829372e6","article-title":"Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol","volume":"19","author":"Paisansinsup","year":"2013","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise","volume":"134","author":"Young","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2019.05.047_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3349\/ymj.2016.57.1.118","article-title":"HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS\/TEN according to culprit drugs","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaip.2019.05.047_bib13","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaip.2019.05.047_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.047_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000354918","article-title":"Clinical features and prognostic factors in severe cutaneous drug reactions","volume":"162","author":"Yang","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.05.047_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/SMJ.0000000000000082","article-title":"Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street","volume":"107","author":"Karis","year":"2014","journal-title":"South Med J"},{"key":"10.1016\/j.jaip.2019.05.047_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","article-title":"Uric acid as a danger signal in gout and its comorbidities","volume":"9","author":"Rock","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4103\/0253-7613.103304","article-title":"Cutaneous adverse drug reaction profile in a tertiary care out patient setting in eastern India","volume":"44","author":"Saha","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jaip.2019.05.047_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-014-1764-0","article-title":"Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA-B*4403 allele and lamotrigine","volume":"71","author":"Park","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2019.05.047_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.047_bib25","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.05.047_bib26","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2019.05.047_bib29","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2019.05.047_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000335624","article-title":"Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management","volume":"97","author":"Shiohara","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaip.2019.05.047_bib31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.coi.2011.05.005","article-title":"The narrowing of the CD8 T cell repertoire in old age","volume":"23","author":"Blackman","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaip.2019.05.047_bib32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jid.2017.02.964","article-title":"Epidermal barrier protects against age-associated systemic inflammation","volume":"137","author":"Velarde","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000475802","article-title":"Overlapping DRESS and Stevens-Johnson syndrome: case report and review of the literature","volume":"9","author":"Casagranda","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-7-72","article-title":"Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?","volume":"7","author":"Bouvresse","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2019.05.047_bib35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2019.05.047_bib36","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.05.047_bib37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.jaip.2019.05.047_bib38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1468-3083.2012.04502.x","article-title":"SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population","volume":"27","author":"Hu","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2019.05.047_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib40","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/ijd.12466","article-title":"A\u00a0clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis","volume":"54","author":"Bansal","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2019.05.047_bib41","first-page":"73","article-title":"A\u00a010-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia","volume":"73","author":"Loo","year":"2018","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jaip.2019.05.047_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FPC.0000000000000285","article-title":"Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population","volume":"27","author":"Saksit","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2019.05.047_bib43","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3349\/ymj.2017.58.3.604","article-title":"Value of serum cystatin C measurement in the diagnosis of sepsis-induced kidney injury and prediction of renal function recovery","volume":"58","author":"Leem","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaip.2019.05.047_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11606-015-3480-6","article-title":"Low ALT levels independently associated with 22-year all-cause mortality among coronary heart disease patients","volume":"31","author":"Peltz-Sinvani","year":"2016","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jaip.2019.05.047_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cld.2016.08.003","article-title":"Drug-induced acute liver failure","volume":"21","author":"Habib","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jaip.2019.05.047_bib46","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaip.2018.09.014","article-title":"The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts","volume":"7","author":"Trubiano","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.047_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819305434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819305434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:19:10Z","timestamp":1761974350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819305434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2213219819305434"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.05.047","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.05.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}